Compare KTOS & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTOS | ELAN |
|---|---|---|
| Founded | 1994 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 11.6B |
| IPO Year | 1999 | 2018 |
| Metric | KTOS | ELAN |
|---|---|---|
| Price | $75.77 | $24.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $97.44 | $27.63 |
| AVG Volume (30 Days) | 4.0M | ★ 4.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | $751,900,000.00 | ★ $4,715,000,000.00 |
| Revenue This Year | $25.63 | $8.61 |
| Revenue Next Year | $23.29 | $4.90 |
| P/E Ratio | $615.38 | ★ N/A |
| Revenue Growth | ★ 12.44 | 6.22 |
| 52 Week Low | $27.51 | $8.02 |
| 52 Week High | $134.00 | $27.72 |
| Indicator | KTOS | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 50.67 |
| Support Level | $70.49 | $23.72 |
| Resistance Level | $81.53 | $25.64 |
| Average True Range (ATR) | 5.12 | 0.97 |
| MACD | -1.17 | 0.11 |
| Stochastic Oscillator | 2.85 | 67.94 |
Kratos Defense & Security Solutions Inc develops and fields transformative, affordable technology, platforms, and systems. The company has two segments; The Kratos Government Solutions (KGS) segment is comprised of an aggregation of KGS operating segments, including its microwave electronic products, space, training, and cybersecurity, C5ISR/modular systems, turbine technologies, and defense and rocket support services operating segments and The Unmanned Systems segment consists of unmanned aerial, unmanned ground, unmanned seaborne and related command, control, and communications system businesses. The company derives a majority of its revenue from the Kratos Government Solutions segment.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.